prnewswire.comSmart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines3 months ago
prnewswire.comBlood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points4 months ago
CashuGT Biopharma Advances Immuno-Oncology with IND Application for GTB-5550 Targeting Solid Tumors2 months ago
CashuGT Biopharma's Innovative NK Cell Engagers Transforming Precision Oncology Landscape2 months ago
CashuGT Biopharma Innovates Immuno-Oncology with Advanced Therapy GTB-3650 for Blood Cancers3 months ago